Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 4/20 | 0.52 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137244 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SOAT1MEN1FAAH | |
| SCHEMBL6385811 | 0.93 | HMGCR (0.56) | HMGCRPTPN7SOAT1MEN1FAAH | |
| SCHEMBL6385815 | 0.93 | HMGCR (0.56) | HMGCRPTPN7SOAT1MEN1FAAH | |
| SCHEMBL6138507 | 0.87 | HMGCR (0.68) | HMGCRPTPN7MEN1KMT2AKDM4E | |
| SCHEMBL6389166 | 0.87 | HMGCR (0.68) | HMGCRPTPN7MEN1KMT2AKDM4E | |
| SCHEMBL6137527 | 0.81 | HMGCR (0.48) | HMGCRPTPN7MEN1CYP3A4KMT2A | |
| SCHEMBL6137532 | 0.81 | HMGCR (0.48) | HMGCRPTPN7MEN1CYP3A4KMT2A | |
| SCHEMBL6138656 | 0.81 | HMGCR (0.48) | HMGCRPTPN7MEN1CYP3A4KMT2A | |
| SCHEMBL6138650 | 0.81 | HMGCR (0.48) | HMGCRPTPN7MEN1CYP3A4KMT2A | |
| SCHEMBL6137269 | 0.80 | HMGCR (0.73) | HMGCRPTPN7MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038259-A1 | Hydroxyeicosenoic acid anaglogs | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1425258-A4 | HYDROXYEICOSENOIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1425258-A2 | HYDROXYEICOSENOIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003024390-A2 | HYDROXYEICOSENOIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038259-A1 | Hydroxyeicosenoic acid anaglogs | HCAR1, HRH4, HCAR3 | HMGCR 226/4885PTPN7 2459/4885SOAT1 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.